Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shalev, E.
Right arrow Articles by Ben-Ami, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shalev, E.
Right arrow Articles by Ben-Ami, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 10, pp. 2541-2544, 1995
© 1995 European Society of Human Reproduction and Embryology

research-article

Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment

E. Shalev1, Y. Geslevich, M. Matilsky and M. Ben-Ami

Fertility Unit, Department of Obstetrics and Gynecology, Central Emek Hospital Afula 18101, Israel

Correspondence: *To whom correspondence should be addressed

The objective of this study was to compare hormonal response, luteal phase adequacy and pregnancy and abortion rates in patients randomized to receive human chorionic gonadotrophin (HCG) or gonadotrophinreleasing hormone agonist (GnRHa) during ovulation cycles stimulated by clomiphene citrate. Anovulatory patients received either one s.c. dose of tryptorelin (0.1 mg; n = 104) or one i.m. dose of HCG (10 000 IU; n = 106) after clomiphene citrate stimulation had induced enlarged ovarian follicles (>17 mm in diameter). A short-lived, transitory increase in serum luteinizing hormone (98 ± 9 IU/1) and follicle-stimulating hormone (30 ± 5 IU/1) concentrations was measured at 12 h following the injection of GnRHa, and these concentrations returned to baseline levels by 36 h post-injection. Midluteal progesterone concentrations were similar in both groups (>10 ng/ml), and the mean luteal phase duration was also not significantly different (13 days). There were no significant differences in the mean number of pregnancies (12.0 versus 12.6% per cycle) and the abortion rate (18.2 versus 12.5%) between the GnRHa- and HCG-treated groups respectively. There were no complications related to treatment in either group. The results show that a relatively low dose of GnRHa can be used in place of HCG to induce ovulation in clomiphene citrate-treated patients.

Key words: clomiphene citrate/GnRH agonist/HCG/ovulation induction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
R. van de Lagemaat, C.M. Timmers, J. Kelder, C. van Koppen, S. Mosselman, and R.G.J.M. Hanssen
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor
Hum. Reprod., March 1, 2009; 24(3): 640 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. Humaidan, H. Ejdrup Bredkjaer, L. Bungum, M. Bungum, M.L. Grondahl, L. Westergaard, and C. Yding Andersen
GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study
Hum. Reprod., May 1, 2005; 20(5): 1213 - 1220.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.